Immunotherapy of cancer through targeting of minor histocompatibility antigens.

Abstract

Minor histocompatibility antigens are allogeneic targets of T-cell mediated graft-versus-tumour effects following allogeneic stem cell transplantation. Recent research has identified several minor histocompatibility antigens as tumour proteins and has also disclosed their unique properties in both the induction and the effector phase of graft-versus-tumour effects. Targeting tumour-specific minor histocompatibility antigens by adoptive immunotherapy will battle against tumour tolerance and evoke allo-immune responses, thereby enhancing graft-versus-tumour effects against leukaemia and solid tumours. Recently acquired knowledge of the role of donor immunisation status, new techniques in the generation of minor histocompatibility antigen-specific cytotoxic T lymphocytes in vitro, and innovative principles in vaccination will help to design clinical trials that exploit minor histocompatibility antigens in the immunotherapy of cancer.

• Authors: Lothar Hambach, Els Goulmy
• Journal: Current opinion in immunology (Curr Opin Immunol) Vol. 17 Issue 2 Pg. 202-10 (Apr 2005) ISSN: 0952-7915 [Print] England
• PMID: 15766682 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Cancer Vaccines
• Minor Histocompatibility Antigens

Topics

• Animals
• Cancer Vaccines
• Graft vs Host Disease (immunology)
• Humans
• Immunotherapy
• Minor Histocompatibility Antigens (immunology)
• Neoplasms (immunology, therapy)
• Stem Cells (immunology)